2-(2-Thienyl)ethyl p-Toluenesulfonate CAS 40412-06-4 Purity >99.0% (HPLC) Clopidogrel Hydrogen Sulfate Intermediate Factory

Short Description:

Chemical Name: 2-(2-Thienyl)ethyl p-Toluenesulfonate

CAS: 40412-06-4

Purity: >99.0% (HPLC)

Appearance: White Solid Powder

Clopidogrel Hydrogen Sulfate Intermediate (CAS 135046-48-9)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply, High Purity, Commercial Production
Chemical Name: 2-(2-Thienyl)ethyl p-Toluenesulfonate
CAS: 40412-06-4

Chemical Properties:

Chemical Name	2-(2-Thienyl)ethyl p-Toluenesulfonate
Synonyms	2-(2-Thienyl)ethyl Toluene-p-Sulphonate; 2-(Thiophen-2-yl)ethyl 4-Methylbenzenesulfonate
CAS Number	40412-06-4
CAT Number	RF-PI998
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C13H14O3S2
Molecular Weight	282.37
Melting Point	30.0 to 34.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White Solid Powder
Purity / Analysis Method	>99.0% (HPLC)
Loss on Drying	≤1.0%
2-(3-Thienyl)ethyl Toluene-p-Sulphonate	≤0.10%
Residue on Ignition	≤0.50%
Total Impurities	<1.0%
Test Standard	Enterprise Standard
Usage	Intermediate of Clopidogrel Hydrogen Sulfate (CAS: 135046-48-9)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

2-(2-Thienyl)ethyl p-Toluenesulfonate (CAS: 40412-06-4) is an intermediate of Clopidogrel Hydrogen Sulfate (CAS: 135046-48-9). Clopidogrel Hydrogen Sulfate is a new anti-platelet aggregation drug, successfully developed by French Sanofi-Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. Clopidogrel Hydrogen Sulfate inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation.